Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease
Posted inNeurology news Psychiatry

Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease

Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, suggesting that tau staging is essential for identifying metabolic and psychiatric vulnerability in the AD spectrum.
Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score
Posted inGastroenterology news Oncology

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful monitoring despite low PAGE-B scores.